Priosh has a vested interest in a diverse ecosystem of companies that provide comprehensive pharmaceutical solutions. This includes molecular design, formulation, manufacturing, and pre-clinical to clinical research phases (I–IV).
We are particularly focused on supporting startups, virtual, and emerging biotech companies. Through our network of life sciences companies and investors, Priosh provides targeted investments and services designed to accelerate development, reduce timelines, and help our portfolio partners overcome critical bottlenecks on their path to growth.
For example, Priosh is interested in investing in biotech companies with a pivotal Phase 2b go-to-market strategy aimed at securing conditional marketing authorization, an accelerated approval pathway for biotech companies with lead compounds that show promising initial data and can address unmet medical needs.